Klausen M, Justesen S, Pedersen J et al.Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trialThe Lancet, 407, 1687-1698 Herman, Rae J
In spite of promising data, issues remain about standardizing its active components, pharmacokinetics, and lack of large scale human trials
Results tend to be most impressive for acute soft tissue injuries less than 6 months old, while chronic structural damage may respond more slowly or incompletely
According to the Mass Eye and Ear study: 8.9% of diabetic patients taking semaglutide received a NAION diagnosis
Drinking water throughout the dayespecially warm water with lemonhelps manage nausea without adding calories
Eating certain foods while taking GLP-1 agonists may increase your chance of unpleasant side effects